ATXN3 WILDTYPE

ATXN3 is a deubiquitinating enzyme that removes ubiquitin tags from proteins, playing a critical role in cellular protein quality control. In SCA3, also known as Machado-Joseph disease, the ATXN3 gene contains an abnormal expansion of CAG repeats that encode a polyglutamine (polyQ) tract, causing the protein to misfold and aggregate into toxic inclusions in neurons [1][3]. Normal ATXN3 alleles contain 12-44 CAG repeats, while pathogenic alleles have 52 or more repeats, with the Q27 variant analyzed here falling well within the normal range [2]. SCA3 is transmitted in an autosomal dominant manner and represents the most common form of inherited ataxia worldwide [3][7]. The AlphaFold2 structure prediction for the Q27 wildtype ATXN3 achieved an average confidence score (pLDDT) of 72.0, indicating moderate overall reliability. Regions with pLDDT above 70 are generally considered reasonably well-predicted, though areas below this threshold should be interpreted with explicit uncertainty. The ATXN3 protein contains multiple functional domains including ubiquitin-interacting motifs (UIMs) that are critical for its deubiquitinating function [4]. Understanding the normal protein architecture is essential because recent research has shown that truncated variants of Ataxin-3 with UIMs can undergo liquid-liquid phase separation (LLPS), a process that may precede aggregation in disease states [4]. The molecular mechanisms underlying SCA3 pathogenesis involve multiple factors beyond simple polyQ expansion. Research has demonstrated that the mutant Ataxin-3 protein aggregates into neuronal nuclear inclusions that progressively damage cerebellar neurons [1][3]. Single-cell RNA sequencing has revealed impaired heat stress responses in SCA3, suggesting that cellular protein quality control systems become overwhelmed [1]. Additionally, genetic modifiers play important roles: intermediate CAG repeats in ATXN2 (another gene) can influence SCA3 disease progression [5], and single nucleotide polymorphisms near the ATXN3 repeat region may affect disease presentation [2][8]. The repeat tract structure itself, including specific interruptions in the CAG sequence, can influence disease manifestation [2]. Somatic expansion of the CAG repeat over time has emerged as a critical factor in disease progression. Studies using blood and buccal swab DNA from SCA3 patients have shown that the repeat continues to expand in an age-dependent manner throughout life [10]. This ongoing expansion in somatic tissues likely contributes to disease onset and progression, making the rate of somatic expansion a potential therapeutic target. Genome editing approaches using CRISPR/Cas9 have shown promise in experimental models, with successful targeting of the expanded ATXN3 gene leading to improvements in cellular structures like the Golgi apparatus [6]. Understanding how cellular factors regulate Ataxin-3 aggregation is also advancing: the protein Rad23B has been shown to delay the liquid-to-solid phase transition of Ataxin-3 through heterotypic buffering mechanisms [4]. The Q27 wildtype structure provides an important reference point for understanding how polyQ expansion disrupts normal protein function. With moderate prediction confidence, this structural model can inform comparisons with expanded variants in regions where pLDDT exceeds 70, though conclusions about poorly predicted regions should be drawn cautiously. Currently, there are no effective treatments for SCA3, and the disease remains a significant clinical challenge characterized by progressive gait instability, coordination problems, and neurodegeneration [3]. Patient-derived induced pluripotent stem cells (iPSCs) are being developed as research tools to better understand disease mechanisms and test potential therapies [9], while genetic analysis techniques including whole genome sequencing are improving diagnostic accuracy for detecting pathogenic CAG repeat expansions [7].